首页> 外文期刊>Journal of clinical gastroenterology >The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications Real-World Evidence From the CONTOR Study
【24h】

The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications Real-World Evidence From the CONTOR Study

机译:从传染媒介研究中对IBS-C或CIC患者患者肠道趋势对肠道运动满意度的影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Goals: This study aimed to characterize the impact of stool consistency on patient-reported bowel movement (BM) satisfaction in patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation, with a focus on linaclotide. Background: As new medications for constipation become available, understanding patients' perceptions of treatment effects may help clinicians manage patient expectations and inform clinical decision-making. Materials and Methods: Data were derived from the Chronic Constipation and IBS-C Treatment and Outcomes Real-world Research Platform (CONTOR) study from 2 patient-reported 7-day daily BM diaries to create a dataset of 2922 diaries representing 26,524 BMs for 1806 participants. Binary variables were created for: medication(s) used in the past 24 hours and categorization of BMs as loose or watery stools (LoWS), hard or lumpy stools (HoLS), or intermediate (neither LoWS nor HoLS). The relationship between stool consistency, medication use, and BM satisfaction was analyzed using logistic regression with SEs corrected for repeated observations. Results: BMs characterized as intermediate stools and LoWS were satisfactory more often (61.2% and 51.2%, respectively) than HoLS (19.4%). Participants who reported taking linaclotide rated a similar proportion of BMs as satisfactory when described as LoWS (65.6%) or intermediate (64.1%). Linaclotide use was associated with higher odds of BMs being reported as satisfactory compared with nonlinaclotide use (odds ratio: 1.23, P<0.05). Conclusions: Overall, CONTOR participants were more likely to report BMs classified as LoWS or intermediate as satisfactory, versus HoLS. Participants taking linaclotide were more likely to be satisfied, particularly those reporting LoWS, versus those not taking linaclotide.
机译:目标:本研究旨在表征大便一致性对患者报告的肠综合征患者患者报告的肠综合征患者的影响(IBS-C)或慢性发作性便秘,重点关注Linaclotide。背景:随着便秘的新药物可用,了解患者对治疗效果的看法可能有助于临床医生管理患者期望并提供临床决策。材料和方法:数据来自慢性便秘和IBS-C治疗和结果现实世界研究平台(Consoror)研究从2例患者报告的7天每日BM日记创建26,524 BMS的2922日记日的数据集参与者。创建二进制变量:过去24小时内使用的药物和BMS的分类为松散或水粪(低温),硬或块状凳子(HOL),或中间(既不低低调也没有HOL)。使用对重复观察的SES进行逻辑回归分析粪便一致性,药物使用和BM满意度之间的关系。结果:BMS作为中间凳子和低点的表现较高(分别为61.2%和51.2%)比HOL(19.4%)。报告的参与者将LinaClotide评定为类似于BMS的比例与低点(65.6%)或中间体(64.1%)进行令人满意。与非嵌入式使用相比,LinaClotide使用与令人满意的令人满意的BMS令人满意的用途(差距:1.23,P <0.05)。结论:总体而言,传感器参与者更有可能将BMS报告为低点或中级作为满意的,与HOL。参与者患有LinaClotide的人更有可能得到满足,特别是那些报告的低点,而不是那些没有服用LinaClotide的人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号